Merck says long-term cholesterol drug study met primary endpoint
November 17, 2014 at 08:46 AM EST
Nov 17 (Reuters) - Merck & Co said on Monday that its long-term Improve-It trial, which was aimed at showing whether its Zetia and Vytorin franchise does more than reduce "bad" cholesterol, had met its primary endpoint.
